Navigation Links
Temple researchers show targeted cancer drug may stunt heart's ability to repair itself
Date:11/6/2012

(Philadelphia, PA) Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.

Studying mice with the equivalent of a heart attack, researchers found that the drug sorafenib (Nexavar) which inhibits proteins called tyrosine kinase receptors (RTKs), and is used in kidney and liver cancer treatment can interfere with heart stem cell activity, affecting the heart's ability to repair itself after injury. The findings suggest that sorafenib and other similar drugs that target these kinds of protein receptors may raise the risk for heart attack for some cancer patients with underlying heart disease, as well as affect the heart's ability to repair damage. By understanding how these cancer drugs can affect the heart, scientists and clinicians may be able to devise new treatment strategies to lessen such potentially damaging effects of often vital cancer drugs.

"The goal is not to take the drug off of the market it's a very good and useful drug that cancer patients need. We're trying to understand how this cancer drug and others like it can affect the heart, and what types of individuals might be at risk for problems," said senior author Steven Houser, PhD, Professor and Chair of Physiology at Temple University School of Medicine and Director of Temple's Cardiovascular Research Center. "Our results are beginning to provide a clearer picture of some of the potential physiological mechanisms at play."

Dr. Houser, first author Catherine Makarewich, a graduate student, and their co-workers reported their findings November 5, 2012 at the Late-Breaking Basic Science Session at the American Heart Association's Scientific Sessions in Los Angeles.

Sorafenib is a member of a broad class of anticancer drugs called targeted therapies that halt cancer growth, rather than necessarily trying to eliminate the disease. Termed a "multi-kinase" inhibitor, sorafenib blocks the activity of a range of protein enzymes and specific targets in the cell that can contribute to the development and growth of cancer. In this case, sorafenib inhibits several RTKs, including c-kit, a receptor found on cardiac progenitor cells in heart and bone marrow, and can prevent the cardiac stem cell population from growing. Such progenitor and stem cell populations play important roles in cardiac repair.

Mortality Rates Following Induced Heart Attacks

The researchers wanted to see if they could better understand the mechanism behind these toxic effects. In the study, normal mice were given sorafenib for a week before being made to have the equivalent of a heart attack, and compared to mice that had a heart attack without receiving the drug. After one week, the mice that received sorafenib had significantly worse heart damage than the other group. Only 40 percent of those mice, versus 72 percent of the other group, were alive after one week. According to Dr. Houser, the doses were equivalent to those cancer patients would typically receive. Sorafenib by itself had no discernible effect on the mice prior to heart attack.

"Our study was to see if such a drug would put individuals with cancer and ischemic heart disease at extra risk for a heart attack," he said. "Mice given sorafenib and then made to have the equivalent of ischemic disease and a heart attack had much poorer heart function and survival. The drug put the animals at much greater risk for heart damage and death compared to animals without the drug."

Cancer patients tend to be middle-aged and older, and often have other significant health issues, including underlying heart disease. As a result, in patients with ischemic heart disease, there is already damage under repair. Drugs such as sorafenib may block or slow this repair process and increase the risk for a heart attack, Dr. Houser said.

Repair Process Inhibited

The researchers subsequently treated bone marrow stem cells, heart stem cells, and heart muscle cells (myocytes) with sorafenib in the laboratory dish. The drug blocked both types of stem cells from growing, but had no effect on normal heart muscle cells. This meant that the drug likely doesn't affect normal heart cells that were not damaged and under repair, Dr. Houser pointed out. "Injury activates the proliferation of the stem cells," he said. "We think it's something about the repair process that the drug affects."

He and his team would like to find drugs that could be taken alongside cancer drugs such as sorafenib that would reduce adverse effects on heart stem cells. At this time, they are developing a program to screen candidate agents. "Ideally, we could help physicians predict which patients are at higher risk for these effects, and find better ways to screen patients," Dr. Houser said.

The investigators next plan to test therapies to stimulate repair and protect hearts from potential damage from such cancer drugs.


'/>"/>
Contact: Steven Benowitz
steven.benowitz@tuhs.temple.edu
215-707-4784
Temple University Health System
Source:Eurekalert

Related medicine news :

1. Penn-Temple team discovers gatekeeper for maintaining health of cell energy source
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Researchers Find Gene Mutations That May Be a Key to Autism
6. Researchers find evidence of banned antibiotics in poultry products
7. NJ stroke researchers report advances in spatial neglect research at AAN Conference
8. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
9. Researchers Map Brain Regions Linked to Intelligence
10. Researchers ID Genes That May Determine Mental Illness
11. Researchers Develop Blood Test for Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... a not-for-profit organization responsible for clinical transfusion research programs and for the blood ... Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... technology and recruiting support, is pleased to announce the promotion of Mike Mackey ... as the Market Manager where he was responsible for managing client projects and ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. , ... security software, is featured in the current issue of Silicon Review ... with innovative technology solutions and features them in their magazine. The magazine allows ...
(Date:6/23/2016)... ... 23, 2016 , ... Representatives of CHA Fertility Centers (CFC), one of the ... Dr. Joshua J. Berger. As of May 2016, Dr. Berger will serve as ... Berger has received recognition for his research, his teaching and his patient care. After ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
Breaking Medicine Technology: